Relay Therapeutics, Inc. Form 4 Filings

Relay Therapeutics, Inc. (RLAY) reports that Chief Financial Officer Thomas Catinazzo sold 17,717 shares of common stock on September 8, 2026 at a weighted average price of $18.94 per share in a sale in the open market or a private transaction. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025 and was executed in multiple trades at prices ranging from $18.34 to $19.25. Following this transaction, Catinazzo beneficially owns 122,851 shares, including 6,538 shares underlying restricted stock units, held directly.

Relay Therapeutics, Inc. (RLAY) President and CEO Sanjiv Patel reported a sale of 48,199 shares of common stock on September 8, 2026 at a weighted average price of $18.94 per share, executed pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025.

After this sale, he holds 519,500 shares directly and additional shares indirectly through family irrevocable trusts, for which he disclaims beneficial ownership.

Relay Therapeutics, Inc. (RLAY) reported that Chief Corporate Development Officer Peter Rahmer sold 4,508 sharesRule 10b5-1 trading plan$20.03 per share223,657 shares6,102 shares underlying restricted stock units

Relay Therapeutics, Inc. (RLAY) reported that entities associated with SoftBank sold 6,000,000 shares of its Common Stock on August 25, 2026, in a sale classified as an open market or private transaction at $19.40 per share. The shares are held of record by SVF Pauling (Cayman) Limited, a wholly owned subsidiary of SoftBank Vision Fund (AIV M2) L.P., with SB Investment Advisers (UK) Limited acting as alternative investment fund manager and exclusively responsible for acquisition, financing, voting and disposal decisions. Following this transaction, the reporting structure indicates 21,904,963 shares of Relay Therapeutics Common Stock remain held indirectly by these entities.

Relay Therapeutics, Inc. (RLAY) reported that President and CEO Sanjiv Patel sold 48,199 shares of common stock on August 17, 2026 in an open-market transaction at a weighted average price of $20.33 per share, effected pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025. Following this sale, he directly held 567,699 shares of common stock. Additional shares totaling 199,548 and 687,355 are held in separate irrevocable trusts for the benefit of his family members, with an independent trustee; Patel disclaims beneficial ownership of those trust-held securities.

Relay Therapeutics, Inc. (RLAY) reported that its Chief Financial Officer, Thomas Catinazzo, sold 17,717 shares of common stock on August 14, 2026 in an open-market transaction at a weighted average price of $19.74 per share, under a previously adopted Rule 10b5-1 trading plan. After this sale, he directly holds 140,568 shares of Relay Therapeutics common stock, which include 6,538 shares underlying restricted stock units.

Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo reported the sale of 1,459 shares of common stock on July 28, 2026 at $18.61 per share. The shares were sold solely to cover income tax withholding from the vesting of 3,269 RSUs, with no discretion by the officer and in line with company policies. After the sale, he beneficially owns 158,285 shares, including 6,538 shares underlying RSUs.

Relay Therapeutics, Inc. officer Peter Rahmer, Chief Corporate Development Officer, had 748 shares of common stock sold on July 28, 2026 at $18.61 per share to cover income tax withholding from the vesting of 3,051 RSUs. He had 228,165 shares remaining afterward, including 6,102 shares underlying RSUs, and no discretion over the tax-related sale, which followed the company’s RSU vesting policies.

Relay Therapeutics, Inc. executive Donald A. Bergstrom, President of R&D, reported the sale of 2,237 shares of common stock on July 28, 2026 at $18.61 per share. The sale covered income tax withholding on the vesting of 5,012 RSUs on July 27, 2026. After the transaction, he directly held 407,660 shares, including 10,025 shares underlying RSUs.

Relay Therapeutics’ President of R&D, Donald A. Bergstrom, reported an open-market sale of 8,660 shares of common stock at a weighted average price of $18.71 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, he directly holds 409,897 shares, including 15,037 shares underlying restricted stock units.

Relay Therapeutics, Inc. President and CEO Sanjiv Patel reported routine equity activity involving company common stock. On June 30, 2026, he acquired 3,056 shares through the company’s Employee Stock Purchase Plan at $6.95 per share, a plan-based purchase described as exempt under Rule 16b-3.

On July 7, 2026, he sold 48,199 shares of common stock in an open-market transaction at a weighted average price of $19.58 per share, executed in multiple trades between $18.52 and $20.20 pursuant to a pre-established Rule 10b5-1 trading plan adopted on October 30, 2025. Following these transactions, Patel directly holds 615,898 shares of Relay Therapeutics common stock.

Separate from his direct holdings, irrevocable trusts for the benefit of his family members hold 687,355 shares and 199,548 shares of common stock, respectively, with an independent trustee. Patel disclaims beneficial ownership of the shares held in these trusts.

Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo sold 17,717 shares of common stock in open-market transactions on July 6, 2026 at a weighted average price of $18.69 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025, meaning the sales were scheduled in advance.

The sale was completed in multiple trades at prices ranging from $18.39 to $19.38 per share. After these transactions, Catinazzo directly owns 159,744 shares of Relay Therapeutics common stock, which includes 9,807 shares underlying restricted stock units.

Relay Therapeutics, Inc. officer Peter Rahmer reported a sale of 50,000 shares of common stock on June 30, 2026 at a weighted average price of $19.09 per share, executed in multiple trades pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2025. He also acquired 3,056 shares at $6.95 per share. After these transactions he directly holds 228,913 shares, including 9,153 shares underlying restricted stock units.

Relay Therapeutics, Inc. reported that Chief Financial Officer Thomas Catinazzo exercised stock options and sold common shares in a series of same-day transactions. He exercised options for a total of 169,446 shares of common stock at exercise prices of $4.45, $5.22, and $5.04 per share. He then completed open-market sales totaling 187,163 shares at prices reported around $16.97–$17.01 per share, executed in multiple trades within disclosed price ranges. Following these transactions, he directly owned 177,461 shares of common stock, which include 9,807 shares underlying restricted stock units. The filing notes that at least one of the reported transactions was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025.

Relay Therapeutics, Inc. reported that President, R&D Donald A. Bergstrom exercised options for 93,456 shares of common stock at $4.12 per share and sold 93,456 shares at a weighted average price of $16.94 per share in multiple trades ranging from $16.15 to $17.39, pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025.

After these transactions, he directly holds 418,557 shares of common stock, including 15,037 shares underlying restricted stock units. The exercised option, which was fully vested and had an expiration date of April 9, 2028, now has no remaining balance.

Relay Therapeutics director Claire Mazumdar received a new stock option grant. The Form 4 reports an award of options covering 32,947 shares of Relay Therapeutics common stock at an exercise price of $14.09 per share. These options vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that date and expire on June 8, 2036. After this grant, Mazumdar holds stock options for 32,947 underlying shares directly.

Relay Therapeutics director Habib J. Dable received a new stock option award covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 8, 2036. It vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the company’s next annual stockholder meeting. Following this grant, Dable holds options covering 32,947 underlying shares directly.

Relay Therapeutics director Linda A. Hill received a stock option grant covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and was granted as a compensation award, not an open-market purchase or sale.

The option was granted on June 9, 2026 and vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following that date. The option expires on June 8, 2036 if not exercised.

Relay Therapeutics, Inc. director Alexis Borisy reported receiving a stock option award covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 8, 2036.

According to the filing, the option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that grant date. This is a compensation-related grant, not an open-market purchase or sale of shares.

Relay Therapeutics director Douglas S. Ingram received a grant of stock options covering 32,947 shares of common stock. The options carry an exercise price of $14.09 per share and were granted as a compensation-related award, not an open-market purchase or sale.

According to the terms, the award vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the next annual meeting of stockholders following that grant date. After this grant, Ingram holds options for 32,947 underlying shares.

Relay Therapeutics director Mark Murcko received a new stock option award. The grant covers 32,947 shares of common stock at an exercise price of $14.09 per share and expires on June 8, 2036.

According to the terms, the option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that date. After this award, Murcko holds options for 32,947 shares directly.

Relay Therapeutics, Inc. director Lonnel Coats received a new stock option grant covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and was granted on June 9, 2026 as compensation, not an open-market purchase.

The option vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, and expires on June 8, 2036. Following this grant, Coats holds stock options for 32,947 underlying shares directly.

Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo sold 17,717 shares of common stock in an open-market transaction at a weighted average price of $12.86 per share. The trade was carried out under a Rule 10b5-1 trading plan adopted on October 30, 2025.

After this sale, he directly holds 195,178 shares, which include 9,807 shares underlying restricted stock units. The transaction was executed in multiple trades at prices ranging from $12.67 to $13.42 per share.

Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo had 972 shares of common stock sold on April 28, 2026 at $14.79 per share. According to the disclosure, this transaction was executed to cover his income tax withholding obligations from the vesting of 3,268 restricted stock units on April 27, 2026 and he had no discretion over the sale, which followed company policies.

After this tax-related sale, Catinazzo beneficially owned 212,895 shares of Relay Therapeutics common stock, including 9,807 shares underlying restricted stock units.

Relay Therapeutics, Inc. executive Peter Rahmer reported an open-market sale of 753 shares of common stock at $14.79 per share. According to the footnotes, the sale was made solely to cover income tax withholding on the vesting of 3,051 restricted stock units and was not discretionary. After this transaction, Rahmer directly owns 275,857 shares of Relay Therapeutics common stock, including 9,153 shares underlying RSUs, indicating the sale was small relative to his overall position.

Relay Therapeutics, Inc. President of R&D Donald A. Bergstrom reported a small, tax-related share sale. On April 28, 2026, he sold 1,490 shares of common stock at $14.79 per share. A footnote explains the sale covered income tax withholding on 5,012 RSUs that vested on April 27, 2026 and that he had no discretion over the transaction, which followed company policies for RSU vesting. After this sale, he directly holds 418,557 shares, including 15,037 shares underlying RSUs.

Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo reported option exercises and share sales. On April 9, 2026, he exercised a stock option to acquire 1,800 shares of common stock at $5.22 per share and then sold 1,800 shares at $15.00 per share.

On April 7, 2026, he sold an additional 17,717 shares of common stock at a weighted average price of $13.01 per share, with trades executed between $12.42 and $13.46. The filing states these transactions were made under a Rule 10b5-1 trading plan. After these transactions, he directly owns 213,867 shares, including 13,075 shares underlying restricted stock units.

Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo reported an open-market sale of 17,717 shares of common stock on March 9, 2026 at a weighted average price of $10.06 per share. The trades were executed at prices ranging from $9.77 to $10.35 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025. Following this transaction, he directly holds 231,584 shares of Relay Therapeutics common stock, which include 13,075 shares underlying restricted stock units.

Relay Therapeutics President of R&D Donald A. Bergstrom reported automatic sales of common stock to cover tax withholding on recently vested RSUs. On January 27, 2026, 18,895 shares were sold at $7.62 per share, and on January 28, 2026, 2,686 shares were sold at $8.45 per share.

The footnotes state these transactions were executed without his discretion under company policies when 59,550 and 9,072 RSUs vested. After these transactions, he beneficially owned 420,047 shares, including 20,049 shares underlying RSUs.

Relay Therapeutics officer reports ESPP purchase and tax sales. Chief Corporate Development Officer Peter Rahmer bought 994 shares of Relay Therapeutics common stock on December 31, 2025 under the 2020 Employee Stock Purchase Plan at $2.99 per share, a transaction the company notes is voluntarily reported.

On January 27, 2026 he sold 11,684 shares at $7.62 per share, and on January 28, 2026 he sold 1,354 shares at $8.45 per share. Footnotes state both sales were made only to cover income tax withholding on vesting RSUs, with no discretion over the sales. After these transactions, he beneficially owned 276,610 shares, including shares underlying RSUs.

Relay Therapeutics Chief Financial Officer Thomas Catinazzo reported automatic share sales tied to restricted stock unit (RSU) vesting. On January 27, 2026, he sold 13,820 shares of common stock at $7.62 per share, and on January 28, 2026, he sold 1,695 shares at $8.45 per share.

Footnotes state both transactions were sales of shares to cover income tax withholding obligations upon the vesting of 42,394 and 5,724 RSUs, and that he had no discretion over the sales under company policies. After these transactions, he beneficially owned 250,996 and then 249,301 shares, including shares underlying RSUs.

Relay Therapeutics, Inc. reported that Donald A. Bergstrom, its President of R&D, received a grant of stock options on January 13, 2026. The award covers 575,000 stock options, each representing the right to buy one share of common stock at an exercise price of $7.94 per share. Following this grant, Bergstrom beneficially owns 575,000 derivative securities directly.

The options are designed to vest over time. According to the disclosure, the shares underlying this option will vest in sixteen equal quarterly installments after January 13, 2026, and each vesting date requires Bergstrom to continue his service with the company. This structure aligns the award with ongoing tenure and performance in his executive role.

Relay Therapeutics, Inc. reported an insider equity award for Chief Corporate Development Officer Peter Rahmer. On January 13, 2026, he received a stock option covering 475,000 shares of common stock at an exercise price of $7.94 per share.

According to the filing, the shares underlying this option vest in sixteen equal quarterly installments after January 13, 2026, contingent on his continued service with the company through each vesting date. Following this grant, Rahmer beneficially owned 475,000 derivative securities directly in the form of this stock option.

Relay Therapeutics, Inc. reported that President and CEO Sanjiv Patel received a stock option grant. On January 13, 2026, he was awarded an option to buy 1,450,000 shares of Relay Therapeutics common stock at an exercise price of $7.94 per share. The filing states that the shares underlying this option will vest in sixteen equal quarterly installments after January 13, 2026, so long as he continues to serve with the company through each vesting date. Following this grant, he beneficially owned 1,450,000 derivative securities directly.

Relay Therapeutics reported that its Chief Financial Officer, Thomas Catinazzo, received a new stock option grant. On 01/13/2026, he was awarded a stock option to buy 400,000 shares of common stock at $7.94 per share. After this grant, he beneficially owns 400,000 derivative securities directly.

The option shares will vest in sixteen equal quarterly installments after January 13, 2026, and each installment requires his continued service with the company through the applicable vesting date. This filing records the award and resulting beneficial ownership rather than any share sale.

Relay Therapeutics, Inc. President and CEO Sanjiv Patel reported both a share purchase and a sale of company stock. On December 31, 2025, he acquired 994 shares of common stock at $2.99 per share under the company’s 2020 Employee Stock Purchase Plan, a transaction described as exempt under Rule 16b-3 and voluntarily reported. On January 6, 2026, he sold 43,168 shares of common stock at $7.82 per share to cover income tax withholding obligations arising from the vesting of 136,854 restricted stock units on January 5, 2026, with no discretion over the sale terms.

After these transactions, he directly held 661,041 shares of common stock, which includes 136,854 shares underlying RSUs. The filing also reports 199,548 and 687,355 shares of common stock held indirectly in irrevocable family trusts with an independent trustee, for which Patel disclaims beneficial ownership.

Relay Therapeutics (RLAY) reported an insider equity award. A company director disclosed a stock option grant to buy 207,931 shares at an exercise price of $6.86 per share on November 4, 2025.

The option expires on November 3, 2035 and vests in 36 equal monthly installments after November 4, 2025, contingent on continued service. The filing indicates direct ownership of the derivative security.

Relay Therapeutics (RLAY) disclosed a director stock option grant to purchase 207,931 shares at an exercise price of $6.86 per share on November 4, 2025.

The option vests in 36 equal monthly installments after November 4, 2025, conditioned on continued service. The option expires November 3, 2035, and the filing lists direct (D) ownership.

Relay Therapeutics (RLAY) reported an insider transaction by its President and CEO (also a Director). On 11/03/2025, the executive sold 62,073 shares of common stock at $7 per share. The filing states this sale covered income tax withholding tied to the vesting of 136,853 RSUs on 10/31/2025, and the executive had no discretion over the sale.

After the transaction, the executive beneficially owned 703,215 shares directly, which includes 136,854 shares underlying RSUs. Additional holdings of 199,548 shares and 687,355 shares are held by irrevocable family trusts; beneficial ownership of those trust shares is disclaimed.

Relay Therapeutics (RLAY) insider transaction: The Chief Corporate Development Officer reported sales of common stock primarily to cover taxes from recent RSU vesting. On October 28, 2025, 19,135 shares were sold at $7.29. On October 29, 2025, 21,394 shares were sold at a weighted average price of $7.50, with trade prices ranging from $7.49 to $7.52.

The sale on October 28, 2025 was to satisfy income tax withholding upon the vesting of 47,897 RSUs on October 27, 2025, and the reporting person had no discretion over that transaction. Following these sales, the reporting person beneficially owns 337,469 shares, which include 108,919 shares underlying RSUs.

Relay Therapeutics (RLAY) reported an insider transaction by its Chief Financial Officer. The CFO sold 21,664 shares of common stock at $7.29 on October 28, 2025. The filing states the sale was to cover income tax withholding tied to the vesting of 48,115 RSUs on October 27, 2025, and the officer had no discretion over the sale under company policy. Following the transaction, the officer beneficially owned 313,631 shares, which includes 110,008 shares underlying RSUs.

Relay Therapeutics (RLAY) officer reports Form 4 transaction. On 10/28/2025, the President, R&D sold 30,897 shares of common stock at $7.29 per share. The filing states the sale was made to cover income tax withholding obligations tied to the vesting of 68,622 RSUs on October 27, 2025, and the reporting person had no discretion over the transaction under company policies.

Following the transaction, the officer beneficially owned 521,823 shares, held directly. This total includes 168,866 shares underlying RSUs.